Drug Research

The rapid emergence of interconnected sensors, wearable devices, and remote-control instrumentation is fundamentally changing the landscape of pharmaceutical research. By creating a responsive and data-rich environment, these innovations allow for greater precision in experimental monitoring and a more comprehensive understanding of complex biological systems, paving the way for more effective therapeutic outcomes.

The integration of machine learning and predictive analytics is revolutionizing the way researchers interpret complex biological datasets. By automating the extraction of insights from massive volumes of raw information, intelligent systems are enabling scientists to identify correlations and potential therapeutic targets that were previously invisible to the human eye.

Ensuring the absolute accuracy and reliability of experimental results is the cornerstone of regulatory compliance and scientific trust. By implementing rigorous frameworks that govern how information is generated, recorded, and stored, research facilities can protect the validity of their findings and maintain a strong position within the global healthcare landscape.

The evolution of pharmaceutical research relies heavily on the integration of robotics and automated liquid handling to maximize throughput and minimize variability. By shifting away from manual labor-intensive processes, research facilities can achieve a level of precision and speed previously unattainable, fundamentally altering the economics of bringing new therapies to market.

AstraZeneca has agreed to acquire Boston-based Modella AI as drugmakers continue to increase their use of artificial intelligence to accelerate research and development. Financial terms of the deal were not disclosed. Modella AI said its foundation models and AI agents...

A number of regulatory changes have been released by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to facilitate clinical research in the country. In order to expedite study approvals while maintaining patient safety, the UK clinical trial...

Teva Pharmaceutical Industries and Royalty Pharma have signed a funding agreement valued at up to $500 million to advance the development of TEV-408, an investigational therapy for autoimmune disorders, including vitiligo. The Teva, Royalty Pharma $500M deal would be...